Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

INSANE: Blueprint medicines proteovant collaboration for protein degrader therapies - The Real Truth

Blueprint Medicines Corporation (NASDAQ:BPMC) and Proteovant Therapeutics have entered a strategic collaboration for targeted protein degrader therapies. 

  • The collaboration will bring Proteovant's Artificial Intelligence (AI)-enhanced targeted protein degradation (TPD) platform and Blueprint Medicine's precision medicine expertise to discover novel targeted protein degraders. 
  • The companies will jointly research important targets and advance up to two novel protein degrader therapies into development candidates. 
  • Proteovant's exclusive partner for TPD, VantAI, will deploy its leading AI technologies for degrader generation and optimization.
  • Upon designation of a clinical development candidate, Blueprint Medicines has the exclusive option to develop and commercialize products resulting from the collaboration. 
  • Proteovant has the option to co-develop and co-commercialize the second of the two Blueprint Medicines-optioned programs in the U.S.
  • Proteovant will receive a $20 million upfront payment and be eligible for an additional $632 million in milestone payments plus tiered royalties from mid-to high-single digits on net sales on the first two programs targets.
  • Price Action: BPMC shares are down 0.16% at $62.08 during the market session on the last check Monday.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.